Professor at Fudan University,Ā China
Di Zhu is a Professor in the Department of Pharmacology at Fudan University, specializing in immuno-oncology and cancer research. Born on October 13, 1983, he holds a Ph.D. in Biochemistry and Molecular Biology. With over 8 years of academic experience, he has pioneered groundbreaking therapies targeting colorectal cancer. Recognized globally for his contributions to cancer immunotherapy, he combines innovative research with clinical applications to improve patient outcomes.
Profile
Scholar
Education š
Ph.D. in Biochemistry & Molecular Biology (2005ā2010), Shanghai Institute of Biochemistry and Cell Biology, CAS. Postdoctoral Fellow (2011ā2015), Dana-Farber Cancer Institute, Harvard University. Undergraduate studies at Shandong University, earning accolades like the National Sci. & Tech. Challenge Cup (2004).
Experience š¼
Researcher: Fudan University, School of Basic Medical Sciences (2021āPresent). Researcher: Minhang & Zhongshan Hospitals, Fudan University (2017āPresent). Researcher: Fudan University, School of Pharmacy (2016ā2021). Led 12 projects, supervised 16 research scholars, and organized 5 workshops globally.
Awards and Honors š
Gold Medal: Global Life & Health Technology Concept Validation (2024). Excellence Award: Hai Ju Ying Cai Global Innovation (2024). Outstanding Young Scientist: Shanghai Society of Biotechnology (2022). 1000 Talent Young Award: CPC Central Committee (2016). Multiple national and international recognitions for cancer research.
Research Focus š¬
Therapies: Pioneered BCL9/Ī²-catenin inhibitors for colorectal cancer. Immunotherapy: Enhanced T-cell responses and reduced immune resistance. Innovative Molecules: Developed selective inhibitors for challenging pathways. Publications: Authored impactful research in top journals, advancing cancer treatment.
Conclusion
Dr. Di Zhu exemplifies the qualities of a world-class researcher. His groundbreaking contributions to cancer therapy, robust academic output, and numerous accolades strongly support his nomination for the Best Researcher Award, affirming his leadership and innovation in the field of pharmacology and immuno-oncology.
Publication
- Clinical cancer immunotherapy: Current progress and prospects
Authors: C Liu, M Yang, D Zhang, M Chen, D Zhu
Journal: Frontiers in Immunology 13, 961805
Citations: 140 (2022)
- Wnt signaling pathway in cancer immunotherapy
Authors: Y Zhou, J Xu, H Luo, X Meng, M Chen, D Zhu
Journal: Cancer Letters 525, 84-96
Citations: 125 (2022)
- IFNĪ± potentiates antiāPD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment
Authors: B Hu et al., including D Zhu
Journal: Cancer Discovery 12 (7), 1718-1741
Citations: 123 (2022)
- The Cyclophilin AāCD147 complex promotes the proliferation and homing of multiple myeloma cells
Authors: DI Zhu et al.
Journal: Nature Medicine 21 (6), 572-580
Citations: 116 (2015)
- Pharmacological inhibition of Ī²-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells
Authors: M Feng et al., including D Zhu
Journal: Science Advances 5 (5), eaau5240
Citations: 100 (2019)
- Cyclophilin A and CD147: Novel therapeutic targets for the treatment of COVID-19
Authors: C Liu, A von Brunn, D Zhu
Journal: Medicine in Drug Discovery 7, 100056
Citations: 91 (2020)
- T-cell-based immunotherapy in colorectal cancer
Authors: M Feng, Z Zhao, M Yang, J Ji, D Zhu
Journal: Cancer Letters 498, 201-209
Citations: 67 (2021)
- Targeting the tumor immune microenvironment for cancer therapy in human gastrointestinal malignancies
Authors: Y Zhang et al., including D Zhu
Journal: Cancer Letters 458, 123-135
Citations: 55 (2019)
- Targeting Cyclophilin A and CD147 to Inhibit Replication of SARS-CoV-2 and SARS-CoV-2-Induced Inflammation
Authors: F Yang et al., including D Zhu
Journal: Molecular Pharmacology
Citations: 1 (2023)
- New Approaches Targeting Immuno-oncology and Tumor Microenvironment
Authors: D Zhu, F He
Book Chapter: Cancer Treatment: An Interdisciplinary Approach, 63-90
Citations: 1 (2022)